Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Spectrum Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Non-Hodgkins Lymphoma

Tumors

Hodgkins Disease

Treatments

Drug: VLI

Study type

Interventional

Funder types

Industry

Identifiers

NCT00364676

HBS501

Details and patient eligibility

About

This Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease.

Full description

The objectives of this study are:

To assess the safety and tolerability of treatment with VLI.
To determine the maximum tolerated dose (MTD) of VLI.
To characterize the pharmacokinetic (PK) profile of VLI.
To explore preliminary tumor response of VLI.

Enrollment

67 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed solid tumor refractory to standard therapy or for which no standard therapy is known to exist, or relapsed and/or refractory non-Hodgkin's lymphoma or Hodgkin's disease
Adequate hematologic, hepatic and renal functions as defined by laboratory tests.
At least 18 years of age.
Have a life expectancy of at least 12 weeks.
Patients must give written informed consent.
ECOG or Zubrod performance status of 0, 1, or 2.

Exclusion criteria

Primary tumors of central nervous system (CNS). Symptomatic brain metastases (unless patient is stable without requirement of steroids and/or antiseizure medications for at least 3 months) or leptomeningeal tumor involvement.
Prior chemotherapy or radiotherapy within 4 weeks prior to study entry (6 weeks for nitrosoureas and mitomycin C).
Planned concurrent systemic therapy and/or radiotherapy drug study treatment.
Use of investigational drugs, biologics or devices within 28 days prior to study treatment or planned use during the course of the study.
Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
Prophylactic hematologic growth factors administered less than or equal to 2 weeks prior to start of therapy with VLI (excluding darbepoetin alfa, epoetin alfa).
Female patients who are pregnant or lactating.
Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent.